CXCL8 and hepatocellular carcinoma: Nevertheless, a recent report from Sakamoto et al. suggested that iguratimod therapy for 6 weeks in a hepatocellular carcinoma xenograft model resulted in lower IL-8 levels, angiogenesis, and number and size of the tumors than those in the control group, suggesting that iguratimod may have some antitumor effects.95 Other studies have reported that iguratimod is associated with hepatocellular toxicity in noncancer patients and experimental models.96 Therefore, the use of iguratimod to treat hepatocellular carcinoma metastases cannot be overlooked.